Our Company
Revolutionizing transcranial Doppler (TCD) ultrasound through the application of robotics, artificial intelligence, and the cloud.
Our Mission
In 2023, NeuraSignal proudly acquired the business of NovaSignal; yet our origin story traces back a decade earlier. Originally known as NovaSignal, our foundation was laid in 2013 with a single-minded mission: to facilitate greater access to crucial medical data, enabling physicians to profoundly enhance patient care.
The foundational technology behind NeuraSignal was developed by Co-Founder Dr. Robert Hamilton during his Ph.D. studies in the Department of Neurosurgery at UCLA. Dr. Hamilton’s extensive hands-on experience in the neurocritical care unit, coupled with his international research pursuits in countries like Haiti, China, and Malawi, served as the backdrop to our story. In these regions, where medical technological access was often restricted, he witnessed firsthand the need for reliable data to improve patient outcomes.
This profound realization and the subsequent introduction to MBA students Dan Hanchey and Leo Petrossian marked the inception of NeuraSignal. Together, they embarked on a journey of innovation and commitment, which continues to impact lives and redefine medical technology standards across the globe.
Working with NeuraSignal has been an outstanding experience from the very beginning. The team has been professional, responsive, and exceptionally supportive throughout the entire process.
The advent and use of the NG2 robotic-assisted TCD has transformed clinical practice regarding PFO closure at the Royal Columbian Hospital. After routine implementation of NG2, PFO closure rates have grown ~4-fold in our program and continue to increase.
The Calgary Stroke Program is committed to advancing stroke care – globally. We leverage NeuraSignal’s automated and manual TCD technologies to capture critical neurovascular data non-invasively. This enables our physicians to make calculated treatment decisions in real-time.
Since implementing NeuraSignal’s world’s 1st and only automated, robotic TCD (NG2) we’ve isolated critical findings, such as embolization, in real-time, that would otherwise be missed. This technology can radically improve clinical and financial value for any private neurology clinics in the USA.
Making a difference in communities across the globe
The inspiration behind NeuraSignal traces back to the country of Malawi in sub Saharan Africa. It was here that co-founder, Robert Hamilton utilized transcranial doppler ultrasound as a tool to research pediatric malaria and sickle cell anemia. The challenges of this resource-constrained environment underscored the need for automation and broader technological access. In line with their commitment to advancing healthcare, NeuraSignal recently donated eight Lucid™ TCD systems to Nationwide Children’s Hospital, supporting the establishment of specialized research centers focused on malaria and sickle cell anemia throughout sub-Saharan Africa .
As Director of Operations for the Neurosciences at South Shore University Hospital, I have been impressed by the innovation, responsiveness, and partnership provided by NeuraSignal. Their technology has helped advance our neurovascular diagnostic capabilities while supporting efficient clinical workflows and high-quality patient care. The NeuraSignal team has consistently demonstrated professionalism, expertise, and a strong commitment to improving outcomes in neuroscience and stroke care.
NeuraSignal is not affiliated with Novarad, read more here.